Clinical Trials Logo

Esophagitis, Peptic clinical trials

View clinical trials related to Esophagitis, Peptic.

Filter by:

NCT ID: NCT01599858 Completed - Reflux Oesophagitis Clinical Trials

Effect of Repeated Doses of YF476, Omeprazole and Placebo on Stomach Acidity in Healthy Volunteers

Start date: August 1996
Phase: Phase 1
Study type: Interventional

The objectives of this study were: To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal- and food- stimulated gastric pH in healthy volunteers. To compare repeated doses of YF476 at 2 dose levels, placebo and omeprazole with respect to their effect on basal and meal stimulated pH. To assess the safety, tolerability and pharmacokinetics of repeated doses of YF476 in healthy volunteers.

NCT ID: NCT01597674 Completed - Reflux Oesophagitis Clinical Trials

Effect of 5, 10 or 25 mg of YF476 Daily for 14 Days on Stomach Acidity in Healthy Volunteers

Start date: April 1997
Phase: Phase 1
Study type: Interventional

The objective of the study was to assess whether the tolerance to the effect of YF476 on gastric pH observed with repeated doses in a previous study in healthy volunteers can be avoided by using smaller doses of YF476.

NCT ID: NCT01562639 Completed - Clinical trials for Repeatedly Recurring Esophagitis

Nexium Capsules RE Maintenance Specific Clinical Experience Investigation

Start date: April 2012
Phase: N/A
Study type: Observational

The purpose of this study is to collect following data in patients given Nexium capsule (Nexium) in usual post-marketing use as the maintenance therapy for repeatedly recurring/relapsing reflux oesophagitis.

NCT ID: NCT01560598 Not yet recruiting - Reflux Esophagitis Clinical Trials

Adipokines and the Risk of Reflux Esophagitis

Start date: June 2012
Phase: N/A
Study type: Observational

We aimed to risk faoctors for GERD and association between visceral obesity, plasma adipoline(leptin, adiponectin, IL-6, TNF-α)and development of reflux esophagitis in healthy Koreans.

NCT ID: NCT01538849 Completed - Reflux Esophagitis Clinical Trials

Study to Investigate the Safety, Tolerability and Efficacy of YH4808 in Patients With Reflux Esophagitis

Start date: December 2012
Phase: Phase 2
Study type: Interventional

This study is to investigate the optimal clinical dose and administration methods of YH4808 in patients with reflux esophagitis by evaluating the safety and efficacy after YH4808 oral administration.

NCT ID: NCT01538797 Completed - Reflux Oesophagitis Clinical Trials

Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States

Start date: July 1996
Phase: Phase 1
Study type: Interventional

The objectives of the study were: - To compare a single dose of YF476 at 3 dose levels, placebo and ranitidine with respect to their effects on basal- and food- stimulated gastric pH in healthy volunteers. - To assess whether there is a relationship between the pharmacokinetics of YF476 and gastric pH in healthy volunteers. - To assess the safety and tolerability of single doses of YF476 in healthy volunteers.

NCT ID: NCT01538784 Completed - Reflux Oesophagitis Clinical Trials

Safety, Tolerability and Pharmacokinetics of Single Rising Doses of YF476, a Gastrin Antagonist, in Healthy Men

Start date: May 1996
Phase: Phase 1
Study type: Interventional

The objectives of the study were: - To assess the safety, tolerability and pharmacokinetics of YF476 in healthy volunteers. - To select a dose or doses of YF476 for detailed pharmacodynamic studies in healthy volunteers.

NCT ID: NCT01536080 Completed - Clinical trials for Non-erosive Reflux Disease (NERD)

Analysis of GERD Symptoms Using Gastroesophageal Reflux Impact Score Questionnaire for Quality of Life

Start date: July 2008
Phase: N/A
Study type: Observational

Even the patients complain GERD symptoms such as heartburn and acid regurgitation the final diagnosis could be reflux esophagitis (RE), non-erosive reflux disease (NERD) and even functional heartburn (FH). In addition, the GERD symptoms are consisted of esophageal symptoms and extraesophageal symptoms. Thus it is necessary to use effective tool for the measurement of GERD symptoms and response of proton pump inhibitor in short time. Several questionnaires have been made for the assessment of GERD symptoms in recent years However, their screening tools do not include the impact of symptoms on everyday life and take a long time to complete the questionnaires. The GERD impact scale (GIS) questionnaire has been developed to compensate for this. It is a simple, one-page, questionnaire to communicate to the doctor the frequency of reflux symptoms and their effect on quality of life, recognizing that it might also prompt clinicians to make appropriate treatment for patients' symptoms. However, there was no report regarding comparison of the characteristics and response to PPI in RE, NERD and FH groups using GIS questionnaire so far.

NCT ID: NCT01503476 Completed - Clinical trials for Gastro Esophageal Reflux Disease

Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance

Start date: February 2012
Phase: Phase 4
Study type: Interventional

Study Hypothesis: This study is designed as an integral part of the development of new or improved features or components of the Bravo® pH Monitoring System and may serve verification and validation purposes The study population will include a group of healthy volunteers (Group A) and a group of symptomatic patients with known or suspected gastroesophageal reflux disease (Group B). Group A: Healthy volunteers will not undergo invasive procedure. These volunteers may be asked to carry the capsule and\or Bravo Recorder. These procedures will serve to evaluate different technical matters such as human interface, ergonomic aspects and communication performances of the system Group B: Symptomatic patients will undergo invasive procedure, including Bravo capsule delivery, positioning and attachment. Confirmation of capsule attachment may be done by endoscopically. These procedures will serve to evaluate overall system performance in actual clinical setup, for instance: Bravo Recorder performance including communication quality, human interface and similar, ergonomics of delivery device, pH Capsule performance, etc. Subjects from both study groups as well as physician may be asked to provide feedback on the procedure and/or document their activities during the procedure.

NCT ID: NCT01472939 Completed - Clinical trials for Gastroesophageal Reflux Disease

Selective 5-HT4 Receptor Agonist and Proton Pump Inhibitor (PPI) in Subjects With Gastroesophageal Reflux Disease (GERD)

Start date: February 27, 2012
Phase: Phase 2
Study type: Interventional

The aim of this study is to establish a dose-related effect of a selective 5-HT4 receptor agonist compared to placebo on residual symptoms (regurgitation with or without heartburn) in subjects with GERD who have persistent symptoms while on PPI therapy.